Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Down-regulated in renal cell carcinoma 1 (DRR1) (DRR1)
- Target
- DRR1
- Molecular classification
- Actin-binding protein, Tumor suppressor, Co-transcription factor
01
Overview
Down-regulated in renal cell carcinoma 1 (DRR1), also known as FAM107A or TU3A, is a protein that is frequently lost or significantly reduced in various malignancies, particularly renal cell carcinoma and gliomas. Located on chromosome 3p21.1, a region often deleted in cancers, DRR1 functions primarily as a tumor suppressor by modulating the actin cytoskeleton and inhibiting cell migration and proliferation. It is known to bind to F-actin and localize to both the cytoplasm and the nucleus, where it may influence gene expression and cell cycle progression. In the central nervous system, DRR1 plays a role in synaptic plasticity and has been linked to stress-related neuropsychiatric conditions. While there are currently no approved drugs directly targeting DRR1, it is a subject of research for gene therapy and as a prognostic biomarker. Its ability to induce apoptosis and arrest the cell cycle makes it an attractive candidate for therapeutic restoration in deficient tumors.
- Other names
- FAM107ATU3AProtein FAM107ADown-regulated in renal cell carcinoma protein3p21.1 gene 1 protein
02
Mechanism of action
Restoration of expression or modulation of downstream actin-cytoskeleton signaling pathways
03
Biological functions
Actin filament organizationCell migrationCell proliferationApoptosis regulationNuclear signalingSynaptic plasticity
04
Disease associations
Renal cell carcinomaGliomaLung cancerNeuropsychiatric disordersAstrocytoma
05
Safety considerations
Potential for off-target effects on synaptic plasticity in the central nervous systemChallenges in delivering tumor suppressor restoration therapiesRisk of disrupting normal actin cytoskeleton dynamics in healthy cells
06
Biomarkers
DRR1 mRNA expression levelsDRR1 protein expression (immunohistochemistry)Promoter methylation status
Beyond the preview
Go deeper on Down-regulated in renal cell carcinoma 1 (DRR1) (DRR1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Down-regulated in renal cell carcinoma 1 (DRR1) (DRR1).